# Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

> **NCT06246786** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Virginia G. Kaklamani**

## Conditions studied

- Triple Negative Breast Cancer
- DNA Damage Repair Deficiency

## Interventions

- **DRUG:** Cyclosporin A

## Key facts

- **NCT ID:** NCT06246786
- **Lead sponsor:** Virginia G. Kaklamani
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-07-01
- **Primary completion:** 2025-06-23
- **Final completion:** 2025-06-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to enroll to study.
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06246786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06246786, "Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06246786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*